Valuation
- Market cap
- —
- Revenue TTM
- $14,090,000
- Net income TTM
- $-176,940,000
- PE ratio
- —
- Forward PE
- —
- Profit margin
- —
- Debt to equity
- —
Trading
- Volume
- 500
- Avg volume
- 4,306
- Day's range
- $8.32 – $8.90
- Shares out
- —
- Stochastic %K
- 46%
- Beta
- —
- Analysts
- Strong Sell
- Price target
- —
Company profile
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also...
Show more
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
- Phone
- 31 35 206 2971
- Website
- https://www.newamsterdampharma.com
- Address
- Gooimeer 2-35, Naarden, Netherlands
Latest news
No headlines yet.
